Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Oncology
Erschienen in:

11.08.2023

Cardio-oncology in China

verfasst von: K. Sharma, MBBS, BSc, MSc, Cert, Shanshan Wang, BPharm, MBA, Ying Liu, MD, Yangli Zhang, MD, Tong Liu, MD, PhD, Qingling Zhang, MD, MMed, Qiaoqing Zhong, MD, PhD

Erschienen in: Current Treatment Options in Oncology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Opinion statement

Cardio-oncology is going under rapid development in various areas across an increasing number of provinces in China. However there are still a myriad of challenges that need to be overcome in order to ensure its gradual and consistent expansion. The Cardio-Oncology Knowledge Transfer Model (KTM) forms the basis to allow exponential development of effective cardio-oncology services. This would ensure the implementation of precision-based practice while dynamically evolving cardio-oncology to integrate both Western and Chinese medical practices to become an official clinical sub-speciality in its own right in China, for the ultimate benefit of the patient.
Literatur
1.
Xia Y. Working together to advance cardio-oncology in China. JACC Cardio Oncol. 2020;2:144–5.CrossRef
2.
• Ng CT. Advancing Cardio-Oncology in Asia. Korean Circ J. 2023;53:69–91. This research paper is important because it highlights the importance of cardio-oncology in Asia and the need for further research and collaboration to improve the care of cancer patients with cardiovascular complications.CrossRefPubMed
3.
Liu Y. Emergence, development, and future of cardio-oncology in emergence, development, and future of cardio-oncology in China. Chin Med J (Engl). 2018;131:2640–4.CrossRefPubMedPubMedCentral
4.
Xia Y, Liu J. Cardio-oncology. 4th ed. China Cardio-Oncology Association. 2018
5.
Xia C. Cancer statistics in China and United States, 2022: profiles, and determinants. Chin Med J (Eng). 2022;135:584–90.CrossRef
6.
7.
Lv H, Xia Y. Summary and Prospect. In: Xia Y, Liu J, editors. Manual of cardio-oncological therapeutics. China: People’s Health Publishing House; 2019. p. 295–8.
8.
Li Y. Factors associated with outpatient satisfaction in tertiary hospitals in china: a systematic review. Int J Environ Res Public Health. 2020;17:7070–99.CrossRefPubMedPubMedCentral
9.
Shen X. Analysis of the impact of China’s hierarchical medical system and online appointment diagnosis system on the sustainable development of public health: a case study of Shanghai. Sustainability. 2019;11:6564–90.CrossRef
10.
Zhi L. Running an Internet hospital in China: perspective based on a case study. J Med Internet Res. 2021;23:1–9.CrossRef
11.
12.
Gillebert TC. ESC core curriculum for the general cardiologist (2013). Eur Heart J. 2013;34:2381–411.CrossRefPubMed
13.
•• Tse G. The potential impact of the 2022 ESC Cardio-Oncology Guidelines on Clinical Practice in China. JACC CardioOncol. 2023;5:153–5. This paper is very important because it highlights the need for standardised guidelines for the management of cardio-oncology patients in China, and how the ESC guidelines can help to fill this gap. The paper also provides insights into the potential impact of the ESC guidelines on clinical practice in China and how they can help to improve the care of cancer patients with cardiovascular complications.CrossRefPubMedPubMedCentral
14.
Avila MS. Carvedilol for prevention of chemotherapy-related cardiotoxicity The CECCY Trial. JACC CardioOncol. 2018;71:2281–90.CrossRef
15.
Young AM. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017–23.CrossRefPubMed
16.
Chan JSK. Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study. Curr Probl Cardiol. 2023;48:1–14.CrossRef
17.
Zhang Z. Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version). Chin J Clin Oncol. 2020;47:1027–38.
18.
•• Lyon AR. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International cardio-oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361. This paper holds significant importance as it offers updated and comprehensive guidelines for the management of cardiovascular health in cancer patients, addressing the emerging field of cardio-oncology. The collaboration between esteemed organizations such as the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS) also ensures that the guidelines are based on the latest scientific evidence and expert consensus. Lastly, its publication in the prestigious European Heart Journal grants it wide visibility and influence in the medical community, thereby fostering improved patient care and outcomes.CrossRefPubMed
19.
• Hu H. Global trade pattern of medical devices and China’s trade position: based on data from 2001–2020. Front Public Health. 2022;10:1–10. The paper is important as it highlights the significant growth of China’s medical device industry over the past two decades and its increasing role in the global market. The findings of this study are important for policy makers and stakeholders in the medical device industry, as they provide insights into the changing dynamics of the global market and the opportunities and challenges for different players in this industry.
20.
Jakovlijevic M. Asian innovation in pharmaceutical and medical device industry - beyond tomorrow. J Med Econ. 2021;24:42–50.CrossRef
21.
• Liu D. Quality control of next-generation sequencing-based In vitro diagnostic test for onco-relevant mutations using multiplex reference materials in plasma. J Cancer. 2018;18:1680–8. Importance of article can be emphasized because it emphasizes the collaborative evaluation of multiple NGS platforms using reference materials provides valuable insights for improving the performance and accuracy of NGS-based cancer in vitro diagnostics.CrossRef
22.
Wang GN. Consensus on anesthetic management of patients with cancer having heart disease after neoadjuvant chemotherapy in China (2021 version). Chin J Clin Oncol. 2022;49:757–63.
23.
Sadler D. Cardio oncology: digital innovations, precision medicine and health equity. Front Cardiovasc Med. 2022;9:1–9.CrossRef
24.
•• Lin H. Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese Electronic health Records Research in Yinzhou (CHERRY) Study. BMJ Open. 2018;8:1–11. This paper is significantly important because it presents a protocol for a large-scale study that aims to use big data to improve cardiovascular care and outcomes in China, where cardiovascular disease is a major public health challenge. The study demonstrates the potential of big data to transform healthcare delivery and improve health outcomes in resource-limited settings.CrossRef
25.
Zhang Y. Applications and challenges of health insurance databases in the field of cardio-oncology. Chin J Pharmacoepidemiol. 2022;31:271–9.
26.
Wang CH. Epidemiological survey of outpatients from cardio-oncology multidisciplinary ambulatory service based on single clinical center. Chin J Clin Med. 2021;28:172–6.
27.
•• Lv XF. Role and molecular mechanism of traditional Chinese medicine in preventing cardiotoxicity associated with chemoradiotherapy. Front Cardiovasc Med. 2022;9:1–18. This paper is important as Traditional Chinese medicine (TCM) has been used for centuries to treat various health issues and has gained attention as a complementary therapy for cancer treatment. The paper also provides insights into the molecular mechanisms of TCM in preventing cardiotoxicity associated with chemoradiotherapy, contributing to the growing body of research on TCM’s potential benefits for cancer patients. The findings of this paper could potentially lead to new treatment options that combine traditional cancer treatments with TCM, improving overall treatment outcomes and reducing the risk of cardiotoxicity.CrossRef
28.
Jiang Y. Effect of traditional Chinese medicine on the cardiovascular diseases. Front Pharmacol. 2022;13:1–14.
29.
Wen HN. Precision cardio-oncology: use of mechanistic pharmacokinetic and pharmacodynamic modeling to predict cardiotoxicities of anti-cancer drugs. Front Oncol. 2022;11:1–9.CrossRef
30.
Sadler D. Practical and cost-effective model to build and sustain a cardio-oncology program. Cardiooncology. 2020;6(9):1–10.
31.
Chen H. Artificial intelligence applications in cardio-oncology: leveraging high dimensional cardiovascular data. Front Cardiovasc Med. 2022;9:1–7
32.
Martinez DS. Artificial intelligence opportunities in cardio-oncology: overview with spotlight on electrocardiography. Am Heart J Plus. 2022;15:1–32.
33.
•• Kwan JM. The role and impact of social media in cardio-oncology during the COVID-19 pandemic. Curr Oncol Rep. 2021;23:1–19. The paper is extremely important as it highlights the significance of social media in cardio-oncology during the COVID-19 pandemic. It emphasises the potential of social media in advancing patient care and enhancing remote communication between healthcare providers and patients. The paper also underscores the importance of collaboration and knowledge-sharing among healthcare professionals and patients to improve treatment outcomes. It contributes to the growing body of literature on cardio-oncology and provides valuable insights into the use of social media in healthcare. The paper is relevant and timely, given the current healthcare landscape.CrossRef
34.
Wang XG. Advances and challenges in pediatric cardio-oncology. Mol Cardiol China. 2020;20:3587–92.
Metadaten
Titel
Cardio-oncology in China
verfasst von
K. Sharma, MBBS, BSc, MSc, Cert
Shanshan Wang, BPharm, MBA
Ying Liu, MD
Yangli Zhang, MD
Tong Liu, MD, PhD
Qingling Zhang, MD, MMed
Qiaoqing Zhong, MD, PhD
Publikationsdatum
11.08.2023
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 10/2023
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01123-x

Weitere Artikel der Ausgabe 10/2023

Correction to: Voluntary Assisted Dying/Euthanasia: Will This Have an Impact on Cancer Care in Future Years?

  • Open Access
  • Correction

Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia

An Update on Temporal Bone Paragangliomas

  • Open Access

Opioid-induced Neurotoxicity in Patients with Cancer Pain

Research Progress on Pyroptosis in Hematological Malignancies

  • Open Access

Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer

  • Open Access

Neu im Fachgebiet Onkologie

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise